Roivant Sciences Ltd. (ROIV) Key Metrics
ROIV valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $24.22B
- Enterprise value
- $22.86B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- — 10-yr median 251.9
- Price / book
- 6.3 10-yr median 2.8
- EV / EBITDA
- 0.7
- Dividend yield
- —
- Beta
- 1.10
ROIV key metrics, FY2019–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsROIV valuation Price multiples at each fiscal year-end price.
ROIV returns How much profit the business earns on the capital it uses.
ROIV per-share figures Results divided by the shares outstanding at year-end.
ROIV financial health Debt, liquidity and how easily interest is covered.
ROIV efficiency & capital use Working capital cycle and where the cash goes.
ROIV valuation history
ROIV returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ROIV debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ROIV cash returned to shareholders
ROIV price vs earnings per share
ROIV key metrics
FY2019–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $19.22B | $7.32B | $8.76B | $5.26B | $3.31B | $6.70B | — | — |
| Enterprise value | $15.03B | $2.53B | $2.72B | $4.06B | $1.53B | $4.81B | — | — |
| P/E ratio | — | — | 2.0 | — | — | — | — | — |
| Price / sales | — | 251.9 | 267.8 | 166.8 | 59.8 | 281.5 | — | — |
| Price / book | 4.2 | 1.6 | 1.5 | 4.5 | 2.0 | 3.5 | — | — |
| EV / sales | — | 87.2 | 83.1 | 128.8 | 27.7 | 202.1 | — | — |
| EV / EBITDA | — | — | 0.6 | — | — | — | — | — |
| Earnings yield | −1.6% | −2.3% | 49.6% | −19.2% | −25.5% | −12.1% | — | — |
| Free cash flow yield | −3.9% | −11.5% | −8.8% | −16.3% | −21.0% | −8.3% | — | — |
| Dividend yield | — | — | 0.1% | 3.1% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 1.7% | 17.7% | 0.1% | 3.1% | — | 0.0% | — | — |
| Share price at fiscal year-end | $27.70 | $10.09 | $10.54 | $7.38 | $4.94 | $9.78 | — | — |
| Per share | ||||||||
| Revenue per share | $0.01 | $0.04 | $0.04 | $0.04 | $0.08 | $0.03 | $0.10 | $0.01 |
| Earnings per share | −$0.43 | −$0.24 | $5.23 | −$1.42 | −$1.26 | −$1.18 | $1.75 | −$4.84 |
| Operating cash flow per share | −$1.08 | −$1.16 | −$0.92 | −$1.18 | −$1.01 | −$0.81 | −$1.11 | −$4.76 |
| Free cash flow per share | −$1.09 | −$1.16 | −$0.92 | −$1.20 | −$1.04 | −$0.81 | −$1.12 | −$4.81 |
| Cash per share | $6.19 | $6.74 | $7.87 | $2.36 | $3.08 | $3.11 | $3.19 | $3.94 |
| Book value per share | $6.52 | $6.46 | $7.18 | $1.62 | $2.47 | $2.77 | $2.97 | $4.35 |
| Tangible book value per share | $6.52 | $6.46 | $7.02 | $1.42 | $2.47 | $2.77 | $2.97 | $4.35 |
| Dividends per share | — | — | $0.01 | $0.23 | — | — | — | — |
| Capex per share | $0.01 | $0.01 | $0.00 | $0.02 | $0.03 | $0.01 | $0.01 | $0.05 |
| Debt per share | $0.15 | $0.14 | $0.60 | $0.68 | $0.42 | $0.36 | $0.26 | $0.66 |
| Shares outstanding | 693.9M | 725.4M | 831.0M | 712.8M | 669.8M | 684.8M | 684.8M | 215.4M |
| Change in shares outstanding | −4.3% | −12.7% | +16.6% | +6.4% | −2.2% | 0.0% | +218.0% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −6.5% | −3.2% | 122.1% | −71.7% | −47.6% | −41.2% | 80.9% | −111.2% |
| Return on invested capital (ROIC) | −846.2% | — | — | — | — | — | −325.4% | −256.1% |
| Return on assets (ROA) | −5.4% | −2.7% | 90.5% | −40.6% | −32.0% | −31.3% | 62.1% | −75.1% |
| Return on tangible assets | −5.2% | −3.2% | 61.4% | −45.0% | −32.7% | −30.1% | 48.5% | −75.1% |
| Income quality (OCF / net income) | — | — | −0.18 | — | — | — | −0.63 | — |
| Financial health | ||||||||
| Total debt | $107.4M | $100.2M | $499.7M | $481.4M | $283.9M | $245.0M | $180.9M | $143.2M |
| Cash & short-term investments | $4.30B | $4.89B | $6.54B | $1.68B | $2.06B | $2.13B | $2.19B | $849.6M |
| Net debt | −$4.19B | −$4.79B | −$6.04B | −$1.20B | −$1.78B | −$1.89B | −$2.00B | −$706.4M |
| Debt / equity | 0.02 | 0.02 | 0.08 | 0.42 | 0.17 | 0.13 | 0.09 | 0.15 |
| Debt / assets | 0.02 | 0.02 | 0.07 | 0.20 | 0.11 | 0.09 | 0.07 | 0.10 |
| Net debt / EBITDA | — | — | −1.31 | — | — | — | — | −5.11 |
| Current ratio | 18.37 | 33.47 | 25.24 | 6.60 | 11.64 | 9.99 | 24.09 | 5.61 |
| Quick ratio | 18.37 | 33.47 | 25.10 | 6.59 | 11.73 | 9.70 | 24.09 | 5.61 |
| Interest coverage | — | — | -23.7 | -28.9 | -172.1 | -381.2 | -69.3 | -99.3 |
| Working capital | $4.89B | $4.85B | $6.47B | $1.53B | $1.96B | $1.97B | $2.13B | $974.2M |
| Invested capital | $339.1M | −$99.1M | −$72.7M | −$42.7M | −$119.6M | $10.0M | $27.6M | $230.9M |
| Tangible asset value | $5.29B | $5.19B | $6.31B | $1.46B | $2.06B | $2.16B | $2.11B | $937.3M |
| Net current asset value | $4.73B | $4.75B | $5.96B | $1.02B | $1.62B | $1.66B | $1.85B | $735.0M |
| Graham number | — | — | $29.08 | — | — | — | $10.82 | — |
| Graham net-net per share | $6.42 | $6.39 | $7.04 | $1.30 | $2.29 | $2.41 | $2.67 | $1.89 |
| Capital allocation | ||||||||
| Dividends paid | — | — | $6.0M | $162.7M | — | — | — | — |
| Share buybacks (net) | $319.5M | $1.29B | $0 | $0 | — | $113,000 | $1.19B | $7.4M |
| Dividend payout ratio | — | — | 0.1% | — | — | — | — | — |
| Capex / revenue | 99.4% | 15.8% | 4.2% | 40.2% | 31.5% | 24.4% | 7.3% | 490.4% |
| Capex / depreciation | 2.45 | 0.33 | 0.06 | 0.67 | 2.94 | 0.98 | 0.83 | 0.02 |
| Stock-based compensation / revenue | 4,190.9% | 994.8% | 610.2% | 690.7% | 1,021.9% | 357.0% | 181.1% | 2,532.7% |
| R&D / revenue | 8,254.4% | 1,894.5% | 1,344.8% | 1,440.1% | 873.7% | 994.4% | 388.9% | 22,073.8% |
| SG&A / revenue | 7,390.6% | 2,035.6% | 1,272.1% | 1,216.1% | 1,401.9% | 1,092.2% | 496.0% | 10,207.1% |
| Efficiency | ||||||||
| Days sales outstanding | 34,901.9 | — | 672.0 | 256.9 | 67.9 | 223.3 | 70.8 | 1,722.9 |
| Days of inventory on hand | — | — | 4,338.5 | -824.2 | 964.9 | 5,666.5 | 0.0 | — |
| Days payables outstanding | 5,921.4 | 15,408.5 | 10,392.5 | 4,355.8 | 1,122.2 | 2,737.6 | 2,668.8 | 3,754.2 |
| Cash conversion cycle (days) | 28,980.5 | — | -5,382.0 | -4,923.1 | -89.4 | 3,152.2 | -2,598.0 | -2,031.3 |
| Receivables turnover | 0.01 | — | 0.54 | 1.42 | 5.38 | 1.63 | 5.16 | 0.21 |
| Payables turnover | 0.06 | 0.02 | 0.04 | 0.08 | 0.33 | 0.13 | 0.14 | 0.10 |
| Inventory turnover | — | — | 0.08 | — | — | 0.06 | 1,131,000.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.01 | 0.04 | 0.00 |
| Average receivables | $789.8M | — | $60.2M | $22.2M | $10.3M | $14.6M | $13.1M | $11.0M |
| Average payables | $20.8M | $38.5M | $45.5M | $36.2M | $27.6M | $15.4M | $8.3M | $6.2M |
| Average inventory | — | — | $19.0M | −$6.9M | $23.7M | $31.9M | $1 | — |
| Intangibles / total assets | 0.0% | 0.0% | 1.9% | 6.1% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ROIV's annual financial statements (latest annual report filed May 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ROIV valuation and financial ratios
Roivant Sciences earned a return on equity of −6.5% and a return on invested capital of −846.2% in fiscal 2026. It ended the year with $107.4 million of debt and $4.3 billion in cash and short-term investments, a net cash position of $4.2 billion. It returned $319.5 million to shareholders: $0 in dividends and $319.5 million in share buybacks. The share count rose 222.2% from 215.4M to 693.9M over 7 years.
See the ROIV income statement, the ROIV chart for price history, or the ROIV stock overview for the latest quote and news.
ROIV key metrics FAQ
What is Roivant Sciences's return on equity?
Roivant Sciences's return on equity (ROE) was −6.5% in fiscal 2026: net income of -$299.8 million on average shareholders' equity of $4.6 billion.
What is Roivant Sciences's ROIC?
Roivant Sciences's return on invested capital was −846.2% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Roivant Sciences have?
Roivant Sciences had total debt of $107.4 million at the end of fiscal 2026, a debt-to-equity ratio of 0.02 and more cash than debt.
Does Roivant Sciences buy back its shares?
Yes. Roivant Sciences spent $319.5 million on net share repurchases in fiscal 2026 Shares outstanding changed −4.3% over the year, to 693.9M..
What is Roivant Sciences's free cash flow yield?
Roivant Sciences generated -$758.6 million of free cash flow in fiscal 2026, a free cash flow yield of −3.9% on its market value at year-end ($19.2 billion).
What is Roivant Sciences's current ratio?
Roivant Sciences's current ratio was 18.37 at the end of fiscal 2026: current assets were 18.37 times current liabilities.